Shares of Artivion plunged nearly 29% in morning trading after the cardiac and vascular surgery device maker reported first-quarter 2026 results. While headline revenue and adjusted earnings beat analyst expectations, management substantially revised its outlook for the year and confirmed a significant acquisition that raised questions about near-term financial commitments.
The company reduced full-year 2026 revenue guidance to a range of $480 million to $496 million, which implies 7% to 11% adjusted constant currency growth versus the prior guidance range of 10% to 14%. At the same time, adjusted EBITDA guidance was lowered to $100 million to $107 million from a previous range of $105 million to $110 million. According to Artivion, the guidance revision was driven by ongoing weakness in U.S. AMDS starter set sales, slower-than-expected international stent graft demand in markets including the Middle East, and certain supply chain bottlenecks that constrained near-term shipments.
Compounding investor concern, Artivion exercised its option to acquire Endospan after the U.S. Food and Drug Administration granted premarket approval for the NEXUS Aortic Arch System. The base purchase price for Endospan is $175.0 million, with an expected net upfront payment of about $135.0 million after accounting for loan offsets. In addition, the agreement includes up to $200.0 million of contingent consideration tied to future product performance.
Management cautioned that U.S. revenue from NEXUS product sales is expected to be negligible for the full year 2026, as the company focuses on building inventory and obtaining value analysis committee approvals ahead of a planned commercial launch on January 1, 2027. The lack of near-term revenue contribution from the acquisition, combined with the upfront cash expected to be paid this year, intensified investor reaction.
Analysts promptly adjusted their price targets following the results and the acquisition announcement. Oppenheimer kept an Outperform rating but cut its price target to $38 from $50. Canaccord lowered its target to $36 from $48 while maintaining a Buy rating, and Citizens trimmed its target to $48 from $53 while retaining a Market Outperform stance.
The stock’s selloff was notable in the context of generally positive U.S. equity markets for the session: the S&P 500 was up 0.67%, the Dow Jones Industrial Average was essentially flat at a 0.01% gain, and the NASDAQ advanced 1.21%. That divergence underscores that pressure on AORT was company-specific rather than market-driven.
Operationally, Artivion reported adjusted EBITDA of $22.08 million for the quarter, which missed analyst estimates of $22.96 million. The midpoint of the company’s full-year adjusted EBITDA guidance equates to $103.5 million, below consensus analyst expectations of $106.5 million. The shares traded down to an intraday 52-week low of $19.16, well under the 52-week high of $48.25.
Despite the market reaction, the underlying quarter showed elements of operational strength: revenue rose 12% year over year, and adjusted EBITDA increased 26%, reflecting what management described as effective cost management and operational leverage. Still, investors appeared to focus on the combination of the lowered full-year outlook, a material, debt-funded acquisition that will not materially contribute to sales in 2026, and subsequent analyst price target reductions.
In short, Artivion’s Q1 performance presented a mix of solid near-term operating trends and strategic moves that weigh on liquidity and near-term growth visibility. The immediate market response sent the stock to its lowest level in over a year during the trading session.